

### Company Overview

Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

### Avalon GloboCare to Present at the 12th Annual LD Micro Main Event on December 10th

Nov 20 2019, 8:30 AM EST

### Avalon GloboCare Enters Agreement to Repurchase 100% of Outstanding Warrants

Oct 21 2019, 8:00 AM EDT

### Avalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies

Sep 19 2019, 8:00 AM EDT

### Stock Overview

Symbol	AVCO
Exchange	Nasdaq
Market Cap	119.15m
Last Price	\$1.54
52-Week	\$1.41 - \$13.50

11/20/2019 04:00 PM EST

### Investor Relations

Crescendo Communications, LLC
T: (212) 671-1020
<a href="mailto:avco@crescendo-ir.com">avco@crescendo-ir.com</a>

### Management Team

#### David Jin

Chief Executive Officer, President and Director

#### Meng Li

Chief Operating Officer, Secretary and Director

#### Luisa Ingargiola

Chief Financial Officer

### Avalon GloboCare Corp.

4400 Route 9 South  
Suite 3100  
Freehold, NJ 07728

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.